Inhibiting novel mechanisms of thrombosis: next-generation antiplatelet therapy

Inhibiting novel mechanisms of thrombosis: next-generation antiplatelet therapy

Bibliographic Details
Main Authors:	Mark R. Thomas, Phillip L. R. Nicolson
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-01-01
Series:	Platelets
Online Access:	http://dx.doi.org/10.1080/09537104.2020.1853422

Similar Items

Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases
by: Maan H. Harbi, et al.
Published: (2021-01-01)

Impact of antiplatelet therapy on microvascular thrombosis during ST-elevation myocardial infarction
by: Sophia Khattak, et al.
Published: (2024-03-01)

ANTIPLATELET THERAPY TO PREVENT THROMBOSIS AFTER HIP FRACTURE - REPLY
by: Macmahon, S, et al.
Published: (1995)

Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses.
by: Melissa Li, et al.
Published: (2014-01-01)

Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs
by: Maan H. Harbi, et al.
Published: (2022-06-01)

Antiplatelet therapy to prevent thrombosis after hip fracture. Rationale for a randomised trial.
by: MacMahon, S, et al.
Published: (1994)

In-Stent Thrombosis after Antiplatelet Therapy Conversion while Awaiting Coronary Bypass
by: Nathan Burke, et al.
Published: (2020-10-01)

Protease‐activated receptor antagonists prevent thrombosis when dual antiplatelet therapy is insufficient in an occlusive thrombosis microfluidic model
by: Jess Berry, et al.
Published: (2022-03-01)

Antiplatelet Agents Inhibit The Generation Of Platelet-Derived Microparticles
by: Alice Giacomazzi, et al.
Published: (2016-09-01)

Novel therapeutics and emerging technology in haemostasis and thrombosis: highlights from the British society for haemostasis and thrombosis annual meeting
by: Claire S. Whyte, et al.
Published: (2023-09-01)

Antiplatelet therapies: An overview
by: Gundu H R Rao
Published: (2016-01-01)

Novel antiplatelet targets in the treatment of acute coronary syndromes
by: Fawaz O. Alenazy, et al.
Published: (2021-01-01)

Bleeding and thrombosis outcomes in hospitalised COVID-19 patients on low-molecular-weight heparin and antiplatelet therapy
by: V Pillay-Fuentes Lorente, et al.
Published: (2022-07-01)

Pharmacologic strategy for one repeated stent thrombosis patient with hyporesponsiveness to standard dual antiplatelet therapy
by: Yi-Shan Lai, et al.
Published: (2015-10-01)

The importance of tests applied to evaluate the effectiveness of antiplatelet therapy in patients with recurrent coronary stent thrombosis
by: Grdinić Aleksandra, et al.
Published: (2009-01-01)

TRIALS OF ANTIPLATELET THERAPY - REPLY
by: Baigent, C, et al.
Published: (1994)

Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
by: Georges Jourdi, et al.
Published: (2021-12-01)

Trials of antiplatelet therapy.
by: Bounameaux, H
Published: (1994)

DURATION OF DUAL ANTIPLATELET THERAPY
by: O. L. Barbarash
Published: (2016-07-01)

What should be done when appropriate antiplatelet therapy fails to prevent stent thrombosis? Two case reports
by: Sungman Hong, et al.
Published: (2023-06-01)

Prevalence of antiplatelet therapy in patients with diabetes
by: Littenberg Benjamin, et al.
Published: (2005-12-01)

Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration.
by: Collins, R, et al.
Published: (1994)

Antiplatelet Therapy Considerations in Women
by: Khadeeja Esmail, et al.
Published: (2019-01-01)

Optimizing antiplatelet / antithrombotic therapy
by: Srijithesh P
Published: (2010-01-01)

Factor XI inhibitors in adjunct to antiplatelet therapy: the ultimate dual-pathway inhibition?
by: Mattia Galli, et al.
Published: (2023-08-01)

Factor XI inhibitors in adjunct to antiplatelet therapy: the ultimate dual-pathway inhibition?
by: Mattia Galli, et al.
Published: (2023-08-01)

PLATELET FUNCTION TEST FOR THE ASSESSMENT OF THROMBOSIS AND BLEEDING RISK IN CHD PATIENTS TAKING ANTIPLATELET MEDICATIONS
by: A. L. Komarov, et al.
Published: (2015-03-01)

Antiplatelet therapy strategies for ischemic stroke
by: M. Yu. Maksimova, et al.
Published: (2017-07-01)

Management of antiplatelet and anticoagulant therapy for endoscopic procedures: introduction to novel oral anticoagulants
by: Martha L. González-Bárcenas, et al.

ANTIPLATELET THERAPY IN THE PREVENTION OF CEREBROVASCULAR ACCIDENTS
by: O. V. Rodionova, et al.
Published: (2017-03-01)

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy—Current Data and Future Directions
by: Nikolaos Spinthakis, et al.
Published: (2018-02-01)

Dual Antiplatelet Therapy (DAPT) versus No Antiplatelet Therapy and Incidence of Major Bleeding in Patients on Venoarterial Extracorporeal Membrane Oxygenation.
by: Dawid L Staudacher, et al.
Published: (2016-01-01)

TIMELINE FOR THE DOUBLE ANTIPLATELET THERAPY. FACTS AND SUGGESTIONS
by: O. L. Barbarash, et al.
Published: (2016-02-01)

Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy
by: Dawkins Keith D, et al.
Published: (2008-02-01)

Antiplatelet therapy in acute cerebral ischaemia.
by: Sandercock, P, et al.
Published: (1999)

Antiplatelet therapy: aspirin for asymptomatic atherosclerosis?
by: Patrono, C, et al.
Published: (2010)

COVID-19 and the Response to Antiplatelet Therapy
by: Tomáš Bolek, et al.
Published: (2023-03-01)

Vorapaxar: The missing link in antiplatelet therapy!
by: Abhijit S Nair
Published: (2017-01-01)

Antiplatelet Therapy in Acute Coronary Syndrome
by: I. M. Kuzmina, et al.
Published: (2022-01-01)

COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome: Concern on antiplatelet factor 4 testing
by: Rujittika Mungmunpuntipantip, et al.
Published: (2023-01-01)